First inclusion of Cerebrolysin^® in TBI guideline!

The Canadian ERABI (Evidence-Based Review of Acquired Brain Injury) guideline included Cerebrolysin^® with a 1b recommendation in the domain attention deficits. This recommendation reflects the high level of evidence supporting the use of Cerebrolysin^® for the treatment of attention deficits in patients with acquired brain injuries.

The Evidence-Based Review of Acquired Brain Injury (ERABI) is a highly respected guideline that provides evidence-based recommendations for the treatment of patients with acquired brain injuries. The guideline is based on a rigorous process of systematic review and critical appraisal of the available literature. The ERABI guideline is designed to help clinicians make informed decisions about the most effective treatments for their patients, taking into account the available evidence, patient preferences, and the clinical context.

The recommendation for Cerebrolysin^® is based on a systematic review of the available literature, which included a number of randomized controlled trials. These studies demonstrated that Cerebrolysin^® is effective in improving attention deficits in patients with acquired brain injuries. The studies also showed that Cerebrolysin^® is safe and well-tolerated, with a low risk of adverse effects.

The importance of the ERABI guideline and the upgrade to a 1b recommendation for Cerebrolysin^® in the domain of attention deficits cannot be overstated. Patients with acquired brain injuries often experience a range of cognitive and behavioral problems, including attention deficits. These deficits can significantly impact their quality of life and their ability to perform everyday tasks.

The ERABI guideline is an important resource for clinicians and researchers involved in the management of patients with acquired brain injuries. The upgrade to a 1b recommendation for Cerebrolysin^® in the domain of attention deficits reflects the high level of evidence supporting its use for the treatment of attention deficits. This upgrade will help to increase awareness of Cerebrolysin^® as a treatment option and will provide clinicians with a clear and evidence-based recommendation for its use.